Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 33)
Adult AML: The Role of Chemotherapy Intensity and Duration. Two Studies of the AML Cooperative Group
Further improvement of chemotherapy for acute myeloid leukemia (AML) requires an evaluation of alternative treatment strategies as investigated in adequate prospective multicenter trials. Since no superior new drugs are available, treatment can be improved only by finding superior treatment strategies and combining them successfully, if possible. The major treatment strategies to be discussed here are
long-term cylic myelosuppressive chemotherapy concepts (maintenance) and
intensified postremission or preremission chemotherapy concepts (intensification).
KeywordsComplete Remission Complete Remission Rate Cytosine Arabinoside Remission Duration Adult Acute Myeloid Leukemia
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Unable to display preview. Download preview PDF.
- 2.Büchner T, Hiddemann W, Wendt F et al. (1987) Early intensification by double induction (DI) in adult AML: a multicenter study of the AML Cooperative Group. Blood 70 [Suppl 1]: 752Google Scholar
- 5.Yates J, Glidewell O, Wiernik P et al. (1982) Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia. A CALGB study. Blood 60: 454Google Scholar
- 6.Sauter C, Fopp M, Imbach P et al. (1984) Acute myelogenous leukaemia. Maintenance chemotherapy after early consolidation treatment does not prolong survival. Lancet i: 379Google Scholar
- 9.Hayat M, Jehn U, Willemze R et al. (1986) A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia. A Leukemia-Lymphoma Group trial of the EORTC. Cancer 58: 617Google Scholar
- 10.Rees JKH, Swirsky D, Gray RG, Hayhoe FGJ (1986) Principal results of the Medical Research Council’s 8th acute myeloid leukaemia trial. Lancet ii: 1236Google Scholar
- 16.Kurrle E, Ehninger G, Fackler-Schwalbe E et al. (1989) Consolidation therapy with highdose cytosine arabinoside. Experiences of a prospective study in acute myeloid leukaemia. In: Büchner T, Schellong G, Hiddemann W, Ritter J (eds) Acute leukemias II - prognostic factors and treatment strategies. Springer, Berlin Heidelberg New YorkGoogle Scholar
- 17.Büchner T, Hiddemann W, Koenigsmann M et al. (1989) Chemotherapy (CT) followed by recombinant human granulocyte macrophage colony stimulating factor ( GM-CSF) for acute leukemias at higher age or after relapse. Proc Am Assoc Cancer Res Am Soc Clin Oncol 8: 770Google Scholar
© Springer-Verlag Berlin Heidelberg 1990